...
首页> 外文期刊>International Journal of Pharmaceutical Sciences and Research >FORMULATION AND EVALUATION OF PROGRAMMED RELEASE OCULAR INSERTS OF MIZOLASTINE
【24h】

FORMULATION AND EVALUATION OF PROGRAMMED RELEASE OCULAR INSERTS OF MIZOLASTINE

机译:咪唑斯汀缓释剂的人工晶状体的制备和评价

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The main objective of this study was to prepare controlled release matrix type ocular inserts of mizolastine for the treatment of seasonal allergic conjunctivitis.The films were prepared by solvent casting technique using Eudragit RL100 and RS100 in different ratios with dibutylphthalate as the plasticizer. The films were evaluated for the physicochemical parameters. In-vitro studies were carried out using Franz-diffusion cell (bi-chamber compartment model)and ex-vivo studies of the optimized formulation were carried out using goat’s cornea. In vivo studies were performed using rabbit as the animal model. Formulations F4andF6, which showed controlled and prolonged in vitro drug release, were subjected to in vivo study. In vitro and in vivo correlation was found to be good, revealing the efficacy of the formulations.Formulation F6 was found to be promising, as it achieved the objective of the present study.
机译:本研究的主要目的是制备控释基质型咪唑斯汀眼用插入剂,以治疗季节性变应性结膜炎。采用溶剂流延技术,以Eudragit RL100和RS100以不同比例与邻苯二甲酸二丁酯作为增塑剂,制备薄膜。评估膜的理化参数。使用Franz扩散池(双腔室模型)进行了体外研究,使用山羊角膜进行了优化配方的离体研究。使用兔子作为动物模型进行了体内研究。显示出受控的和延长的体外药物释放的制剂F4和F6进行了体内研究。发现体外和体内的相关性良好,揭示了制剂的功效。制剂F6被发现是有希望的,因为其实现了本研究的目的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号